Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome

The British Journal of Dermatology
F ChildP L Zinzani

Abstract

Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles. Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT). Secondary end points included global RR, duration of response (DOR) in skin, progression-free survival (PFS), pruritus relief, safety and pharmacodynamic markers. Eight of 26 (25 evaluable) patients achieved ≥ 50% reduction in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%). There was a low global RR of 8%. DOR in skin ranged from 2·8 to 6·9 months. Median PFS was 5·1 months. Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%). Serial tumour biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6. Twenty-one of 26 (81%) patients were withdrawn from the study before or at clinical cut-off; five (19%) continued to receive treatment with quisinostat. The most common drug...Continue Reading

References

Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S SiegelT M Kuzel
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M DuvicUNKNOWN Bexarotene Worldwide Study Group
Feb 5, 2005·Blood·Rein WillemzeChris J L M Meijer
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Aug 10, 2005·Journal of Cellular Biochemistry·Milos Dokmanovic, Paul A Marks
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elise A OlsenMadeleine Duvic
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth L StrevelLillian L Siu
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicola L SteeleJohann S DeBono
Apr 25, 2008·Journal of the National Comprehensive Cancer Network : JNCCN·Steven M HorwitzYoun H Kim
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard L PiekarzSusan E Bates
Oct 29, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janine ArtsPatrick Angibaud
Mar 25, 2010·British Journal of Haematology·Thorsten StühmerRalf C Bargou
Jul 22, 2010·Expert Review of Anticancer Therapy·Cliona GrantSusan E Bates
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sean J WhittakerYoun H Kim
Mar 1, 2011·Blood·Richard L PiekarzSusan E Bates
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elise A OlsenUNKNOWN Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Mar 16, 2012·Future Medicinal Chemistry·Sophia RangwalaMadeleine Duvic
Sep 18, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Madeleine DuvicH Miles Prince
Jun 7, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Balaji VenugopalUdai Banerji
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San-MiguelKenneth C Anderson

❮ Previous
Next ❯

Citations

Aug 4, 2016·The British Journal of Dermatology·J J Scarisbrick
Dec 14, 2017·Assay and Drug Development Technologies·Hermann A M Mucke
Aug 20, 2016·F1000Research·Nooshin Bagherani, Bruce R Smoller
Jan 25, 2019·Current Topics in Medicinal Chemistry·Yan LiBin He
Jan 7, 2020·Expert Review of Hematology·Nada Ahmed, Andrew L Feldman
Apr 15, 2020·Nature Communications·Cristina Morales TorresPaola Scaffidi
Oct 17, 2017·Annual Review of Pharmacology and Toxicology·Volker M LauschkeMagnus Ingelman-Sundberg
Mar 7, 2019·Nature Reviews. Clinical Oncology·David SermerAnas Younes
Jul 10, 2018·Current Medicinal Chemistry·Christophe BlanquartPhilippe Bertrand
Oct 6, 2020·Frontiers in Cell and Developmental Biology·I-Chung ChenJing-Ping Liou
Mar 25, 2018·Current Oncology Reports·Louise PhotiouH Miles Prince
Dec 3, 2020·Frontiers in Oncology·Donglu WuDa Liu
Feb 6, 2021·Pharmaceutics·Taku FujimuraSetsuya Aiba
Feb 13, 2021·Molecular Therapy Oncolytics·Dong YangJian Wang
Apr 13, 2021·Journal of Biomedical Science·Kunal Nepali, Jing-Ping Liou
Feb 12, 2017·Pharmacology & Therapeutics·Subhankar Biswas, C Mallikarjuna Rao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.